Skip to main content
Press Release

Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022

By June 15, 2022No Comments

– Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins –

EDISON, N.J., June 15, 2022 — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced that five abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 (ILC 2022) taking place June 22 – 26, 2022 in London, UK and digitally.

The accepted abstracts for poster presentations are as follows:

Poster #: FRI590
Title: Synergistic anti-tumor activity with a combination of anti-PD1 antibody and the cyclophilin inhibitor, rencofilstat, in the Hep53.4 fatty liver model of hepatocellular carcinoma
Authors: D. Ure1, J. Leslie3, B. Variya1, R. Foster1, J. Mann2, D. Mann2,3
Presenter: Dr. Daren Ure
Session: Liver tumours: Experimental and pathophysiology
Date: 24/06/2022
Time: 09:00 – 18:00
Poster #: FRI591
Title: Rencofilstat, a pan-cyclophilin inhibitor, exerts diverse metabolic and transcriptional anti-tumor activities in a murine NASH-HCC model
Authors: D. Ure1, J. Kuo4, W. Stauffer4, L. Haddon1, C. Fu1, P. Mayo1, R. Foster1, P. Gallay4
Presenter: Dr. Daren Ure
Session: Liver tumours: Experimental and pathophysiology
Date: 24/06/2022
Time: 09:00 – 18:00

Poster #: SAT130
Title: Integrated transcriptomics of rencofilstat treatment in a Phase 2a NASH trial confirms anti-fibrotic effect of pan-cyclophilin inhibition and identifies rencofilstat-specific biomarkers
Authors: P. Mayo1, S. Harrison5, T. Hobbs1, D. Ure1, D. Trepanier1, E. Foster1, C. Zhao1, R. Foster1
Presenter: Dr. Patrick Mayo
Session: NFLD: Therapy
Date: 25/06/2022
Time: 09:00 – 18:00

Poster #: FRI568
Title: Cyclophilin D knockout promotes cell death pathways in preventing HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH
Authors: W. Stauffer6, J. Kuo7, M. Bobardt6, D. Ure1, R. Foster1, P. Gallay6
Presenter: Dr. Winston Stauffer
Session: Liver tumours: Experimental and pathophysiology
Date: 24/06/2022
Time: 09:00 – 18:00

Poster #: THU004
Title: Cyclophilin inhibitor CRV431 as a potential therapy for Alcohol-related Liver Diseases
Authors: Elena Palma8,9, Sara Campinoti8,9, Una Rastovic8,9, Nicola Harris8,9, Omolola Ajayi8,9, Bruna Almeida8,9, Tsin Shue Koay8,9, Sandra Phillips8,9, Daren Ure1, Melissa Preziosi10, Rosa Miquel10, Andreas Prachalias10, Krishna Menon10, Nigel Heato10, Luca Urbani8,9, Shilpa Chokshi8,9
Presenter: Dr. Elena Palma
Session: Alcoholic Liver Disease
Date: 23/06/2022
Time: 09:00 – 18:00

1Hepion Pharmaceuticals; 2FibroFind Ltd; 3Newcastle University; 4Scripps Research Institute; 5Summit Clinical Research; 6Department of Immunology & Microbiology, Scripps Research; 7Arena Pharmaceuticals; 8The Roger Williams Institute of Hepatology, Foundation for Liver Research; 9King’s College London, Faculty of Life Sciences and Medicine; 10Institute of Liver Studies, King’s College London

About Hepion Pharmaceuticals

The Company’s lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was soon followed in December 2021 by the FDA’s acceptance of Hepion’s investigational new drug (IND) application for rencofilstat for the treatment of hepatocellular carcinoma (HCC).

Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence – Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for rencofilstat to expand the company’s footprint in the cyclophilin inhibition therapeutic space.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580

Primary Logo